Neuropathological changes following demyelination in multiple sclerosis (MS) lead to a
reorganization of axolemmal channels that causes conduction changes including …

We evaluated the effects of a non-specific potassium channel blocker, 4-aminopyridine (4-
AP), on chronic experimental autoimmune encephalomyelitis (chEAE) and relapsing …

Voltage-gated K+ (Kv) channels play critical roles not only in regulating synaptic
transmission and intrinsic excitability of neurons, but also in controlling the function and …

As an antagonist of voltage-gated potassium (Kv) channels, 4-aminopyridine (4-AP) is used
as symptomatic therapy in several neurologic disorders. The improvement of visual function …

Multiple sclerosis (MS) is a severely debilitating neurodegenerative diseases marked by
progressive demyelination and axonal degeneration in the CNS. Although inflammation is …

Axon degeneration has been identified as a major contributor to non-remitting neurological
deficits in patients with multiple sclerosis (MS), which has elicited substantial interest in the …

This systematic review summarizes the existing evidence on the effect of 4-aminopyridine (4-
AP) as a symptomatic treatment of decreased walking capacity in patients with multiple …

The development of neuroprotective and repair strategies for treating progressive multiple
sclerosis (MS) requires new insights into axonal injury. 4-aminopyridine (4-AP), a blocker of …

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system
characterized by widespread inflammation, focal demyelination and a variable degree of …

Chronic disability in multiple sclerosis is linked to neuroaxonal degeneration. 4-
aminopyridine (4-AP) is used and licensed as a symptomatic treatment to ameliorate …